JP2025516294A5 - - Google Patents

Info

Publication number
JP2025516294A5
JP2025516294A5 JP2024564785A JP2024564785A JP2025516294A5 JP 2025516294 A5 JP2025516294 A5 JP 2025516294A5 JP 2024564785 A JP2024564785 A JP 2024564785A JP 2024564785 A JP2024564785 A JP 2024564785A JP 2025516294 A5 JP2025516294 A5 JP 2025516294A5
Authority
JP
Japan
Prior art keywords
domain
sequence
human
dna
dnmt3a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516294A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/066436 external-priority patent/WO2023215711A1/en
Publication of JP2025516294A publication Critical patent/JP2025516294A/ja
Publication of JP2025516294A5 publication Critical patent/JP2025516294A5/ja
Pending legal-status Critical Current

Links

JP2024564785A 2022-05-01 2023-05-01 Pcsk9発現のエピジェネティック調節のための組成物及び方法 Pending JP2025516294A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263337167P 2022-05-01 2022-05-01
US202263337164P 2022-05-01 2022-05-01
US63/337,167 2022-05-01
US63/337,164 2022-05-01
US202263355083P 2022-06-23 2022-06-23
US63/355,083 2022-06-23
PCT/US2023/066436 WO2023215711A1 (en) 2022-05-01 2023-05-01 Compositions and methods for epigenetic regulation of pcsk9 expression

Publications (2)

Publication Number Publication Date
JP2025516294A JP2025516294A (ja) 2025-05-27
JP2025516294A5 true JP2025516294A5 (cg-RX-API-DMAC7.html) 2026-05-11

Family

ID=86732155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564785A Pending JP2025516294A (ja) 2022-05-01 2023-05-01 Pcsk9発現のエピジェネティック調節のための組成物及び方法

Country Status (9)

Country Link
EP (1) EP4519293A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025516294A (cg-RX-API-DMAC7.html)
KR (1) KR20250060954A (cg-RX-API-DMAC7.html)
CN (1) CN119836432A (cg-RX-API-DMAC7.html)
AU (1) AU2023265968A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251776A1 (cg-RX-API-DMAC7.html)
IL (1) IL316722A (cg-RX-API-DMAC7.html)
MX (1) MX2024013483A (cg-RX-API-DMAC7.html)
WO (1) WO2023215711A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311610A (en) 2021-09-21 2024-05-01 Scribe Therapeutics Inc Engineered CASX suppressor systems
CN119998446A (zh) 2022-06-07 2025-05-13 斯克里贝治疗公司 用于靶向pcsk9的组合物和方法
CA3260237A1 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
EP4590820A2 (en) * 2022-09-22 2025-07-30 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease
JP2026523341A (ja) 2023-05-15 2026-07-14 エヌクロマ・バイオ,インコーポレーテッド Hbv遺伝子発現のエピジェネティック調節のための組成物および方法
WO2024238723A1 (en) * 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating pcsk9 expression
EP4735603A2 (en) * 2023-06-30 2026-05-06 nChroma Bio, Inc. Guide rna compositions
WO2025106739A1 (en) * 2023-11-14 2025-05-22 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of htt expression
WO2025137650A2 (en) * 2023-12-21 2025-06-26 Nchroma Bio, Inc. Compositions and methods for epigenetic editing
WO2025160155A1 (en) * 2024-01-22 2025-07-31 The Broad Institute, Inc. Epigenetic targeting of prion diseases
WO2025167914A1 (zh) * 2024-02-07 2025-08-14 益杰立科新加坡有限公司 通过表观编辑多靶点治疗疾病的方法
TW202617754A (zh) * 2024-06-21 2026-05-01 大陸商益杰立科(上海)生物科技有限公司 靶向b型肝炎病毒基因的工程化基因轉錄阻抑工具及其用途
CN122295445A (zh) * 2024-06-21 2026-06-26 益杰立科(上海)生物科技有限公司 通过表观编辑靶向调节pcsk9的方法及其用途
TW202617755A (zh) * 2024-06-21 2026-05-01 大陸商益杰立科(上海)生物科技有限公司 靶向pcsk9的工程化基因轉錄阻抑工具及其用途
WO2025261473A1 (zh) * 2024-06-21 2025-12-26 益杰立科(上海)生物科技有限公司 工程化基因转录阻抑工具及其用途
WO2026064753A1 (en) 2024-09-23 2026-03-26 Tune Therapeutics, Inc. Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
WO2026158158A1 (zh) * 2025-01-23 2026-07-30 锐正基因(苏州)有限公司 一种向导rna、其组合物及其在编辑pcsk9基因中的应用
WO2026161895A1 (en) 2025-01-27 2026-07-30 Tune Therapeutics, Inc. Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
EP2566972B1 (en) 2010-05-03 2020-01-15 Sangamo Therapeutics, Inc. Compositions for linking zinc finger modules
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
EP3443081A4 (en) * 2016-04-13 2019-10-30 Duke University CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
AU2019255789B2 (en) * 2018-04-19 2025-11-20 The Regents Of The University Of California Compositions and methods for gene editing
AU2019282149B2 (en) 2018-06-05 2025-08-21 Life Edit Therapeutics, Inc. RNA-guided nucleases and active fragments and variants thereof and methods of use
CN116234902A (zh) 2020-05-04 2023-06-06 利兰·斯坦福青年大学托管委员会 用于激活和沉默基因表达的效应物结构域的生成、鉴定和表征的组合物、系统和方法
EP4158009A4 (en) * 2020-06-02 2024-10-02 The Regents of the University of California Compositions and methods for gene editing
AU2021409729A1 (en) * 2020-12-22 2023-07-13 Nchroma Bio, Inc. Compositions and methods for epigenetic editing
EP4437092A1 (en) * 2021-11-26 2024-10-02 Epigenic Therapeutics Inc. Method of modulating pcsk9 and uses thereof

Similar Documents

Publication Publication Date Title
Chen et al. Loss of Sam50 in hepatocytes induces cardiolipin‐dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury
JP2023145597A (ja) Rnaを編集するための組成物および方法
Ford et al. Protein transduction: an alternative to genetic intervention?
Zahid et al. Identification of a cardiac specific protein transduction domain by in vivo biopanning using a M13 phage peptide display library in mice
Völkers et al. PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity
US6468985B1 (en) Retinoblastoma protein-interacting zinc finger proteins
US20260091120A1 (en) Cell-penetrating peptides
Matsui et al. Protein therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery
US12268749B2 (en) Cell-penetrating peptides
US20060182736A1 (en) Transducible dna-binding proteins
US20180346531A1 (en) Compositions and methods for delivering biotherapeutics
Steinman et al. Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease
KR20220079524A (ko) 접합체 및 이의 용도
US9474781B2 (en) Method for inhibiting cell death during liver failure by administering a caspase recruitment domain
DE69426121T2 (de) Gen grb3-3, variante und ihre verwendungen
JP2016516054A (ja) コレステロール流出を刺激する、減少した毒性を有するペプチド
EP2771367B1 (en) Gigaxonin fusion protein and methods for treating giant axonal neuropathy
JP5700409B2 (ja) Hsp90を標的にした新規抗がんキメラペプチド
JP2024533314A5 (cg-RX-API-DMAC7.html)
US6323335B1 (en) Retinoblastoma protein-interacting zinc finger proteins
Yang et al. Cardiac fibroblasts-specific USP7 drives post-infarction cardiac fibrosis by deubiquitinating Krüppel-like factor 7 to promote myofibroblast activation
US12404307B2 (en) Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
US20230270887A1 (en) Active delivery of nucleic acids and peptides, methods and uses
JP2003530835A (ja) 高トリグリセリド血症を誘発することなくコレステロールレベルを低下するための化合物と方法
US9993521B2 (en) Modulation of scleraxis using a dominant negative scleraxis mutant with a basic DNA-binding domain deletion